Latest Headlines

Latest Headlines

Zika update: Vaccine race swells, PaxVax CEO on how to stop 'chasing epidemics'

As the Zika virus continues to spread, more biotechs are announcing their Zika vaccine programs. Meriden, CT-based Protein Sciences, Atlanta-based GeoVax Labs and Redwood City, CA-based PaxVax are the latest. PaxVax plans to bring its candidate to animal trials during the first half of this year, CEO Nima Farzan told FierceVaccines.

WHO seeks to ease cholera vaccine shortage with EuBiologics approval

In a move aimed at doubling the world's cholera vaccine supply, the World Health Organization has given its nod to South Korean's EuBiologics to provide vaccines under its prequalification program.

FDA accepts PaxVax's BLA for cholera vaccine, grants it priority review

Just a week after announcing a $105 million investment by Cerberus Capital, PaxVax is inching closer to getting its second vaccine--and potentially the first FDA-approved cholera vaccine--to market. The Redwood City, CA-based company announced Wednesday that the FDA accepted for filing and review the Biologics License Application (BLA) for Vaxchora, its cholera candidate.

Cerberus Capital management invests $105M in PaxVax

Redwood City, CA-based PaxVax currently markets one vaccine, Vivotif, the typhoid vaccine it acquired from Johnson & Johnson's Crucell in July 2014. But PaxVax could be on the way to adding its cholera candidate, Vaxchora, to the list thanks to a $105 million investment from Cerberus Capital management.

Nima Farzan takes over as PaxVax CEO

Nima Farzan, who previously served as chief operating officer, will take the helm as CEO of PaxVax, the company announced Monday. Ken Kelley, co-founder and former CEO, will remain on the board of directors and will serve as an advanced leadership initiative fellow at Harvard University.

PaxVax expands commercial network for typhoid vaccine

PaxVax's typhoid vaccine, Vivotif, is licensed for sale in 27 countries. But the Redwood, CA-based company is looking to expand its presence, announcing on Wednesday a series of commercial partnerships and distribution agreements to ensure availability of Vivotif in Australia and Europe.

PaxVax ready to strike M&A; deals that prove its sales model, CEO says

PaxVax entered the M&A; arena last summer, nabbing typhoid vaccine Vivotif from Johnson & Johnson subsidiary Crucell. And it's not stopping there, CEO Ken Kelley says.

PaxVax meets primary endpoints in PhIII cholera vaccine trial

Right now, there is no FDA-approved cholera vaccine for U.S. travelers heading to high-risk countries. A California company hopes to change that soon: On Monday, PaxVax said it planned to submit a Biologics License Application for its oral single-dose candidate in mid-2015.

PaxVax joins the marketed vaccines club with Crucell typhoid buy

PaxVax isn't just a vaccine developer anymore. The company is moving into the vaccines market with the pickup of a typhoid vaccine from Johnson & Johnson subsidiary Crucell, locking up $62 million in financing in the process.

PaxVax nails down $62M to complete vaccine buyout, PhIII study

Redwood City, CA-based PaxVax has nailed down up to $50 million in debt financing and $12 million in a Series B venture funding extension to complete the acquisition of Crucell's oral typhoid vaccine Vivotif and the ongoing Phase III study of its cholera vaccine candidate, PXVX0200.